key: cord-0327600-k737khdf
authors: Miron, J.-P.; Voetterl, H.; Fox, L.; Hyde, M.; Mansouri, F.; Dees, S.; Zhou, R.; Sheen, J.; Mir-Moghtadaei, A.; Blumberger, D. M.; Daskalakis, Z. J.; Vila-Rodriguez, F.; Downar, J.
title: Evaluation of a Novel Therapeutic Repetitive Transcranial Magnetic Stimulation Technique Optimized for Increased Accessibility in Major Depression
date: 2020-06-17
journal: nan
DOI: 10.1101/2020.06.15.20132092
sha: 1d48fbdc54502dad9a03420f95f187b2e374dbda
doc_id: 327600
cord_uid: k737khdf

ABSTRACT BACKGROUND Repetitive transcranial magnetic stimulation (rTMS) is effective in major depressive disorder (MDD). However, technical complexity and operational costs might have been barriers for its wide use and implementation in some jurisdictions, thereby decreasing accessibility. OBJECTIVE Our main goal was to test the feasibility of a novel rTMS protocol optimized for practicality, scalability and cost-effectiveness. We hypothesized that our novel rTMS protocol would be simple to implement and well-tolerated, but less costly and allow for more treatment capacity. METHODS Treatment was administered in an open-room setting, allowing a single technician to attend to multiple patients. Large non-focal parabolic coils held by custom-built arms allowed simple yet efficient and accurate placement. We employed a low-frequency (LF) 1 Hz stimulation protocol (360 pulses per session), delivered on the most affordable FDA-approved devices. MDD participants received an initial accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total), followed by a tapering course of daily sessions (up to 25) to decrease the odds of relapse. The self-reported Beck Depression Inventory II (BDI-II) was used to measure severity of depression. RESULTS Forty-eight (48) patients completed the arTMS course. No serious adverse events occurred, and all patients reported manageable pain levels. Response and remission rates were 35.4% and 27.1% on the BDI-II, respectively, at the end of the tapering course. CONCLUSION If rTMS could be delivered for lower cost at higher volume, while preserving efficacy, safety and tolerability, it could warrant further investigation of this treatment as a first-line intervention in MDD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04376697

for its wide use and implementation in some jurisdictions, thereby decreasing accessibility.

Our main goal was to test the feasibility of a novel rTMS protocol optimized for practicality, scalability and cost-effectiveness. We hypothesized that our novel rTMS protocol would be simple to implement and well-tolerated, but less costly and allow for more treatment capacity. 

Forty-eight (48) patients completed the arTMS course. No serious adverse events occurred, and all patients reported manageable pain levels. Response and remission rates were 35 .4% and 27.1% on the BDI-II, respectively, at the end of the tapering course.

If rTMS could be delivered for lower cost at higher volume, while preserving efficacy, safety and tolerability, it could warrant further investigation of this treatment as a first-line intervention in MDD.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) INTRODUCTION Major depressive disorder (MDD) is a common and disabling illness. Up to 50% of patients experience a chronic or recurrent course, and 30 to 40% develop treatment-resistant depression [1] . Furthermore, although antidepressants offer high convenience and simplicity of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . administration, discontinuation rates approach 50% after 3 months of use due to concern over side effects and non-response [2] . Alternative treatments are therefore needed.

Repetitive transcranial magnetic stimulation (rTMS) is recognized as an effective intervention in MDD, with recent studies and meta-analyses reporting response and remission rates of up to 50-55% and 30-35%, respectively [3] . rTMS has an advantageous side effect profile, with lower discontinuation rates than medication (~5% vs ~25%) [3] . Unfortunately, its widespread adoption is impeded by several obstacles that limit clinical accessibility.

The main issue concerns high acquisition and operation costs, with average cost per remission estimated to be of up to $6,146 in the US [4] . This is partly a result of the equipment needed to deliver high-frequency (HF) protocols, as well as the need for continuous 1:1 technician-patient supervision during treatment. Technical challenges stem from the complexity of the treatment, such as the need for precise positioning of the widely used figure-of-eight (Fo8) focal coils over the target region.

Another area that remains to be refined is treatment course optimization. The current treatment paradigm forces patients to travel to a treatment center every day for 6 weeks in order to receive a full 30 session course. This can be discouraging, especially for working individuals and those who have families. Several studies have explored "accelerated" rTMS (arTMS), whereby multiple stimulation sessions are delivered per day to shorten the overall treatment course duration. Several large trials of arTMS have consistently reported similar or better remission and response rates than conventional once-daily rTMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Furthermore, the total cumulative number of sessions needed to achieve maximal effect is still debated. So far, findings from large rTMS trials have suggested a plateau in clinical response at ~30 sessions, on average [17] . This has recently been challenged by a secondary analysis [18] from the THREE-D trial [19] , demonstrating differences in patients' response trajectories to rTMS.

Indeed, some participants were still showing signs of improvement at 30 sessions (not reaching a plateau), suggesting that a treatment extension might be needed in some individuals.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . To address these issues, we developed a novel rTMS technique optimized for maximum practicality, scalability and effectiveness, while minimizing costs. We employed a safe, welltolerated low-frequency (LF) 1 Hz stimulation protocol on the lowest cost FDA-approved devices, delivered via large parabolic coils held by low-cost custom arms enabling simple yet accurate placement, in an open-room setting enabling supervision of multiple simultaneous sessions. We also tested the effects of 1 Hz arTMS followed by a tapering course of once-daily treatment. These technical refinements are designed to enable the provider to accelerate, increase and maintain treatment response beyond what 'standard of care' rTMS can achieve, while achieving higher patient volumes at lower cost.

We hypothesized that our novel rTMS technique would be safe, well-tolerated and effective, while allowing cost-saving opportunities and therefore increasing accessibility.

We conducted a prospective, single-arm, open-label feasibility study. Participants were recruited after referral to the Poul Hansen Family Centre for Depression neurostimulation specialty clinic, located at the Toronto Western Hospital, an academic healthcare centre which is part of the University Health Network (UHN) in Toronto, Canada.

Adult (18-85 years of age) outpatients were included for study participation if they 1) had a Mini International Neuropsychiatric Interview (MINI) confirmed MDD diagnosis (single or recurrent episode) and 2) maintained a stable medication regimen from 4 weeks before treatment start to the end of the study. We did not require participants to have had a minimal number of failed antidepressant treatment in their current depressive episode. Exclusion criteria were: 1) history of substance dependence or abuse within the last 3 months; 2) concomitant major unstable medical illness; 3) cardiac pacemaker or implanted medication pump; 4) active suicidal intent; 5) diagnosis of any personality disorder as assessed by a study investigator to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . be primary and causing greater impairment than MDD; 6) diagnosis of any psychotic disorder; 7) any significant neurological disorder or insult (including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure confirmed diagnostically by neurological assessment [except those therapeutically induced by ECT], cerebral aneurysm, Parkinson's disease, Huntington's chorea, dementia, stroke, neurologically confirmed diagnosis of traumatic brain injury, or multiple sclerosis); 8) if participating in psychotherapy must have been in stable treatment for at least 3 months prior to entry into the study (with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study); 9) any clinically significant laboratory abnormality in the opinion of the investigator; 10) a dose of more than lorazepam 2 mg daily (or equivalent) currently (or in the last 4 weeks) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy and 11) any non-correctable clinically significant sensory impairment. All participants provided informed consent and this study was approved by the Research Ethics Board of the University Health Network.

Treatment was delivered in an open room setting, allowing up to 4 participants to receive treatment simultaneously, with the help of one or two technicians (Fig. 1) . This was facilitated by an easy-to-use coil placement system, with the Anchored Articulating Arm (AAA) concept at its core (Fig. 2) . AAAs are made out of readily available camera tripod equipment and are anchored at their base to the corner of the treatment chair. Coils are held securely by a clamp locking it to the AAA, maintaining position until treatment has been completed, at which time they can be easily repositioned out of the way. rTMS was delivered through MagPro R20 stimulators equipped with parabolic MMC-140 coils (MagVenture, Farum, Denmark). We recently published a case series on the safety, tolerability, and effectiveness of those coils in MDD [20] . The resting motor threshold (rMT) was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . determined according to standard clinical practice, with the additional need to use the coil's middle ring for stimulation, where the electromagnetic field strength is at its highest [20, 21] . We 1-month follow-up visits were conducted 1-month (± 7 days) after the last tapering session.

Participants who missed any sessions of the arTMS course were withdrawn. All participants were encouraged to complete the tapering course. The study timeline is illustrated in Fig. 3 .

Inventory -II (BDI-II), and research staff administered the Hamilton Rating Scale for Depression 17-item (HRSD-17). On each treatment day, participants also completed the BDI-II and were queried about any adverse events. Self-rated pain intensity of the rTMS procedure was also recorded on a verbal analogue scale (VRS -from 1 [no pain] to 10 [intolerable pain]). We also recorded the number of serious adverse events and reasons for treatment discontinuation when such events occurred. To ensure tolerability, stimulation intensity was adaptively titrated upward as quickly as possible to the target intensity of 120% RMT, without exceeding maximum tolerable pain. We recorded the number of sessions required to reach 120% rMT.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. .

The primary outcome was the degree of improvement following the tapering course as illustrated by response and remission rates on the BDI-II. Secondary outcomes included score changes and percent improvement. The same outcomes are reported on the HRSD-17.

Response was defined as score reductions of ≥ 50% from baseline. Remission was defined as a score of ≤ 12 [23] on the BDI-II and ≤ 7 on the HRSD-17 [24] . We also assessed the number of participants maintaining remission and response from at various timepoints, as well as BDI-II scores trajectory across the entire study. Regarding suicidality, we assessed the number of participants showing remission (number of participants starting with a suicidality score greater than zero at baseline and decreasing to zero at reassessment). Suicidality scores are assessed by item #9 on the BDI-II and item #3 on the HRSD-17.

From March 18 to September 27, 2019, 57 participants with MDD were assessed for eligibility, 7 of whom were ineligible or declined to participate. 50 participants were thus enrolled and started the study. Of these, 2 discontinued treatment during arTMS because of lack of perceived efficacy and were lost to follow-up. 48 participants moved on to the tapering course and were thus included in the final analysis. Of these, 3 participants discontinued before having completed at least 20 sessions of the tapering course because of the lack of perceived efficacy. 45 participants thus completed the entire study, and 35 followed up at 1 month (Fig. 4) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . with a mean of 5.2 ± 3.6 lifetime trials. Average Antidepressant Treatment History Form (ATHF) total score was 4.2 ± 4.3. Average number of trials on the ATHF in the current episode was 1.4 ± 2.6, with 39/48 (81.3%) of participants having had at least one adequate antidepressant trial in their current depressive episode.

Regarding the primary outcome, 35.4% and 27.1% of participants had achieved response and remission on the BDI-II, respectively. Secondary outcomes are presented in Table 2 . On the BDI-II, 10 out 12 (83.3%) who were responders post-acute treatment Table 3 . No participants reported active suicidal intent at any point during the study.

Safety and tolerability outcomes are presented in Table 4 . No serious adverse events (AE) were reported at any point of the study. One patient was withdrawn at session 51 since he reported visual symptoms suggestive of possible retinal detachment but was assessed and cleared by ophthalmology (subsequent diagnosis of migraine equivalent). Overall, 39.6% of participants reported at least one occurrence of an AE at some point during treatment, the most common one having been headache (22.9%). All AEs were reported exclusively during the arTMS course, with the exception of the previously mentioned participant with visual symptoms at session 51. Pain ratings went from 5.6 ± 2.0 on the first treatment, down to 1.9 ± 1.9 on the last treatment. The average rMT was 34.6 ± 5.7% of maximum stimulator output, resulting in a mean target stimulation intensity (120%) of 41.8 ± 6.8%. All participants were able to reach their . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We present preliminary data for a novel rTMS technique optimized for widespread use.

Currently, most guidelines recommend rTMS use solely in treatment-resistant depression (TRD). Specifically, the Canadian Network for Mood and Anxiety Treatments (CANMAT) recommends use in MDD participants who have failed to respond to at least 1 antidepressant [3] , a decision mirrored in other international guidelines [17, 25] . However, access could potentially be broadened if treatments could be delivered safely in more centres, at higher volumes and lower costs, with a faster onset of response. Our study thus attempted to resolve these issues by offering several technical refinements.

First, treatment was delivered in an open-room setting, allowing one or two technicians to treat up to 4 participants in parallel, compared to the usual one-on-one approach.

Even though such a setting could bring about some concerns about technician fatigue and negative patient feedback, this was not reported. We also did not observe any negative . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . interactions between participants that could have jeopardized treatment outcome, and several participants anecdotally gave positive feedback about the more flexible scheduling of treatment sessions enabled by the open setting. Overall, this approach merits qualitative assessment with standardized feedback questionnaires for both technicians and participants. If successful on a larger scale, we believe that this approach may reduce staffing demands, increase clinic capacity and flexibility, and improve cost and accessibility. Given the current COVID-19 pandemic, reduce staffing might be a potential advantage in order to observe physical distancing measures, but it would need to be conjugated with stringent infection control procedures.

One innovation that permitted such a treatment setting was the design and use of our novel AAAs. Standard articulated arms can be more expensive, while offering a limited range of motion. Our AAAs are made of widely available camera tripod equipment and have been both functional and reliable, with no material malfunctions observed. Their durable yet bendable extended branch allowed for the treatment technician to easily and accurately position the coil without tedious joint adjustments. Their anchoring to the treatment chair also eliminated any standalone equipment or cart, creating a more spacious, barrier-free clinic. The mechanical advantage of the anchoring point gives the patient the flexibility to raise or lower the incline of their treatment chair without placement adjustment, as the coil is now anchored to the shifting point of reference, thereby maintaining the coils' targeted area of focus. This custom solution decreased operational complexity, allowing for better patient care, ease of use for the technician, and more efficient use of space and equipment. Similar coil positioning equipment would be relatively straightforward for rTMS manufacturers to adopt in future.

The use of 1 Hz stimulation is another major component allowing for simplified rTMS delivery. Firstly, 1 Hz rTMS is the medically safest stimulation pattern available, having even shown anti-seizure properties in epileptic patients [26] . Further, there exists empirical evidence that 1 Hz rTMS is better tolerated than HF protocols [27] , and also shows similar efficacy [28- . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . 30 ]. With preliminary data potentially showing a higher safety and tolerability profile, LF 1 Hz could be considered in the future as a first line rTMS protocol. Beyond these factors, the greatest advantage of 1 Hz rTMS lies in the low cost of the equipment it requires. HF rTMS require higher-cost stimulators, with expensive cooling systems. 1 Hz rTMS on the other hand can be delivered on more simple stimulators with coils that do not require cooling. This setup is more affordable than the ones required for HF, with the possibility of additional cost reductions in the future through higher volume use.

Parabolic coils also allow simplification of rTMS delivery. We previously published a case report on their use [20] , delineating their potential advantage over Fo8 coils. Indeed, large parabolic coils may require less precise placement given their large electromagnetic field compared to the target brain region -a factor also present with larger helmet-shaped coils [31] .

Also, their central opening allows direct visualization of underlying landmarks, resulting in easier accurate placement over the marked target. We also hypothesized that, given their possibly weaker stimulation of the DLPFC owed to the aforementioned opening, parabolic coils may function by stimulating adjacent neural substrates, such as the orbitofrontal cortex (OFC). Our group also previously published a case series on 1 Hz OFC, which is theorized to be involved in depression [32] [33] [34] .

Another novel aspect of our study was the piloting of accelerated 1 Hz rTMS. We are aware of only one small (n = 7) negative trial with limited stimulation course and duration (18 sessions over 10 days) [35] . Our results are encouraging, but overall limited response and remission rates after the arTMS course would suggest that increasing the number of sessions per day and the number of pulses delivered at each session may be necessary [5] . Indeed, a recent arTMS pilot (n = 6) with highly refractory MDD patients using intermittent theta-burst stimulation (iTBS), 1800 pulses/session, 10 sessions per day over 5 days, reported remission rates of 66% [14] . A larger follow-up study (n = 21) in a less refractory MDD population reported remission rates of up to 90% [36] . The rapid improvement in responders post-acutely (Fig. 5) is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . encouraging, showing that it is indeed possible to rapidly accelerate response to 1 Hz stimulation in some individuals. This could justify the further study of this rTMS technique in more severe inpatient cases, where suicidality is of concern and rapid response is at a premium. Overall, final outcomes post-taper compared favorably to another large trial [19] , as well as a landmark meta-analysis [37] , which may be explained by the high number of total sessions. Supporting this observation, a recent study that offered up to 21 weeks of rTMS reported remission rates of 72% [38] . Since there is a lack of data about 1 Hz arTMS alone without the subsequent tapering period, we are unable to determine the impact or the necessity of such an extension. It may well be possible that 1 Hz arTMS has a delayed effect, where participants would have kept on improving without the extension course, as suggested in other arTMS protocols [12] . Conversely, high relapse rates following arTMS are also of concern [14, 39] .

We also included data regarding suicidality scores for each scale since arTMS has also been studied in the treatment of acute suicidality [6, 8] . In the future, suicidal ideation should be assessed with either the Beck Scale of Suicide ideation (BSI) or the Columbia-Suicide Severity

Rating Scale (C-SSRS).

This preliminary study has several limitations. Of primary concern is the open-label design and the absence of a sham control arm. It is to be expected that the various estimates of effectiveness might be higher than what would be obtained in a randomized, sham-controlled trial, which would represent the next logical step. In addition, the naturalistic approach of the study does not allow estimates of efficacy, but only effectiveness. The design of the study, with multiple reassessments throughout, presented logistical challenges, mainly with patient adherence. Indeed, several participants did not adhere to the planned schedule, and were thus reassessed outside of the planned boundaries. Additionally, we did not qualitatively assess our open-room setting, as discussed previously. We also had 10 participants lost to follow-up at 1month, limiting interpretation of results at that timepoint. In future studies, this would need to be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . corrected to achieve more standardized measures. Furthermore, frequency of tapering course varied between individuals. Although we recommended daily sessions for participants (5 sessions/week), a minimum of 3 sessions/week was tolerated, given the fact that this approach has proven effective on its own [40] . Moreover, results did vary between the self-rated BDI-II and the clinician-rated HRSD-17. Indeed, remission and response rates were higher postacutely and lower post-tapering and at 1-month follow-up visits on the BDI-II compared to HRSD-17. Discrepancies between self-and clinician-rated scales are not unique to our studies and have often been reported in MDD [41] , showing the general limitation of mood scales, and the need for objective biomarkers in psychiatry [42] . As a further matter, the weaker central field in the parabolic coils used may have under-stimulated the DLPFC [20] ; this may be correctable in future by moving the central opening to an intermediate mark between F4, Fz and Cz. Due to their less widespread use in clinical settings, results with 1 Hz rTMS on parabolic coils may not generalize to more commonly used Fo8 coils. The 1 Hz protocol used, although highly tolerable for participants, may also have been less effective due to its limited amount of pulses per session. Given that increased number of pulses has been associated with increased response in 1 Hz rTMS in some studies [43] , it may be advantageous to increase the number of pulses within the same time frame (e.g., 600 pulses in 10 min). Finally, although we did not require participants to meet the usual requirement of TRD in our trial, the majority (>80%) of participants had failed at least one adequate trial. We also did not have a minimal cut-off regarding depression severity on the mood scales for study inclusion, but average baseline scores on the BDI-II was in the severe range. Average HRSD-17 score was also higher than in a recent large trial from our group [19] .

Given its established efficacy in MDD and its lower side-effect profile compared to medication, efforts should be made to make rTMS more accessible to the general public. The current trend depicts increased costs and complexity associated with rTMS administration [14, 36] . However, the techniques demonstrated here may be suitable for safe use in a wider . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . range of settings, and potentially could be adapted in future to enable home use of 1 Hz rTMS. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . Table 2 : Response and remission rates, changes in depression severity scores and percent improvement throughout the study . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. .

Anchored Articulating Arm (AAA) schematic -AAAs are made out of inexpensive camera tripod equipment and are anchored at their base to the corner of the treatment chair. Coils are held securely by a clamp locking it to the AAA, maintaining position until treatment has been completed, at which time they can be quickly twisted out of the way.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. 

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis

Accelerated rTMS: A Potential Treatment to Alleviate Refractory Depression

A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Suicidal Inpatients

Accelerated HF-rTMS in the elderly depressed: A feasibility study

Accelerated Intermittent Theta Burst Stimulation for Suicide Risk in Therapy-Resistant Depressed Patients: A Randomized, Sham-Controlled Trial

Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression_ A fast road to remission?

Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression

Accelerated repetitive transcranial magnetic stimulation in the treatment of depression

Accelerated TMS for Depression: A systematic review and meta-analysis

Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatmentresistant major depressive disorder_ An open label trial

Highdose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression

Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients

Number of pulses or number of sessions? An open-label study of trajectories of improvement for oncevs. twice-daily dorsomedial prefrontal rTMS in major depression

The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder

Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study

Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial

A case series of a novel 1 Hz right-sided dorsolateral prefrontal cortex rTMS protocol in major depression

Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression

The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT

Response and remission criteria in major depression--a validation of current practice

Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)

Low-frequency repetitive transcranial magnetic stimulation for the treatment of refractory partial epilepsy: a controlled clinical study

Low-frequency rTMS is better tolerated than high-frequency rTMS in healthy people: Empirical evidence from a single session study

Response and Remission Rates Following High-Frequency vs. Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Over Right DLPFC for Treating Major Depressive Disorder (MDD): A Meta-Analysis of Randomized

Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes

A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression

Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial

Direct Electrical Stimulation of Lateral Orbitofrontal Cortex Acutely Improves Mood in Individuals with Symptoms of Depression

Orbitofrontal Cortex: A `Non-rewarding' New Treatment Target in Depression?

A non-reward attractor theory of depression

Pilot Study of Accelerated Low-Frequency Right-Sided Transcranial Magnetic Stimulation for Treatment-Resistant Depression

Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression

A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression

Bilateral neuronavigated 20Hz theta burst TMS for treatment refractory depression: An open label study

Is Accelerated, High-Dose Theta Burst Stimulation a Panacea for Treatment-Resistant Depression?

A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments

Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder

Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis

Clinically Meaningful Efficacy and Acceptability of Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Primary